AOD-9604 Alternatives

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials.

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Represents the next evolution beyond dual agonists like tirzepatide, showing unprecedented weight loss in trials.

The lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.

The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.

A dual GLP-1/glucagon receptor agonist in development for obesity and NASH. Combines appetite suppression with increased energy expenditure.